Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
about
Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibitionAdvances in the treatment of rheumatoid arthritis.Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosisUpdate on Janus kinase antagonists in inflammatory bowel disease.Structural basis of recognition of interferon-α receptor by tyrosine kinase 2The arrival of JAK inhibitors: advancing the treatment of immune and hematologic disorders.STAT3 induction of miR-146b forms a feedback loop to inhibit the NF-κB to IL-6 signaling axis and STAT3-driven cancer phenotypesPharmacokinetics, Safety and Tolerability of ABT-494, a Novel Selective JAK 1 Inhibitor, in Healthy Volunteers and Subjects with Rheumatoid Arthritis.Gene mutations and molecularly targeted therapies in acute myeloid leukemia.Effects of sulfasalazine and tofacitinib on the protein profile of articular chondrocytes.Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia.What is the future of targeted therapy in rheumatology: biologics or small molecules?Regulation of cell transformation by Rb-controlled redox homeostasis.Improvement of spontaneous locomotor activity with JAK inhibition by JTE-052 in rat adjuvant-induced arthritis.Interleukin-2 at the crossroads of effector responses, tolerance, and immunotherapyNetwork pharmacology of JAK inhibitorsMLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cellsJanus kinase 1/3 signaling pathways are key initiators of TH2 differentiation and lung allergic responses.The Innovative Medicines Initiative moves translational immunology forward.Tofacitinib: a review of its use in adult patients with rheumatoid arthritis.New targeting strategies in drug therapy of inflammatory bowel disease: mechanistic approaches and opportunities.Protein kinase inhibitors in the treatment of inflammatory and autoimmune diseases.Kinase inhibitors: the next generation of therapies in the treatment of rheumatoid arthritis.Novel treatments with small molecules in psoriatic arthritis.Tofacitinib for the treatment of moderate-to-severe psoriasis.Psoriatic arthritis: latest treatments and their place in therapy.Recent progress and perspective in JAK inhibitors for rheumatoid arthritis: from bench to bedside.Oxindole-based SYK and JAK3 dual inhibitors for rheumatoid arthritis: designing, synthesis and biological evaluation.Design, synthesis, and evaluation of the anticancer activity of 2-amino-aryl-7-aryl-benzoxazole compounds.The Future of Janus Kinase Inhibitors in Inflammatory Bowel Disease.Beyond TNF Inhibitors: New Pathways and Emerging Treatments for Psoriatic Arthritis.Quinoxaline-Based Scaffolds Targeting Tyrosine Kinases and Their Potential Anticancer Activity.Role of interleukin-6 in cancer progression and therapeutic resistance.Kinases as Novel Therapeutic Targets in Asthma and Chronic Obstructive Pulmonary Disease.Effects of tofacitinib on nucleic acid metabolism in human articular chondrocytes.Myeloid cells as a target for oligonucleotide therapeutics: turning obstacles into opportunities.Tumor Necrosis Factor-Alpha and Pregnancy: Focus on Biologics. An Updated and Comprehensive Review.Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitorsInhibition of the JAK/STAT Pathway Protects Against α-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration.Sorafenib analogue SC-60 induces apoptosis through the SHP-1/STAT3 pathway and enhances docetaxel cytotoxicity in triple-negative breast cancer cells.
P2860
Q27683852-EB6AB749-622D-4604-BEFA-7D8CF96DE342Q27691822-1C08AD76-0948-4F33-AD0E-BD1A7B24D71BQ33429617-EF6F9B18-E4D3-4D26-86EB-00CB7DBDED26Q34030650-80AA7886-FE01-4A74-B53F-9F809675575EQ34165581-6D38D4C1-9BE7-4C33-96E7-6A6AC8B6A997Q34349150-507FE5DA-87A4-45B2-B526-3F3820D006D3Q34518047-5142E511-64FD-41D9-AE25-61EC9443897DQ34529981-D0826754-9962-4186-A249-4E031BEDF41EQ34647741-8CAAF92D-864A-4A68-BC47-A4A806E9CD7CQ35064975-655CF750-96BC-4E0D-A3D3-73A85BA98697Q35072638-EC32E5AE-5C84-4FEB-AC57-2B72F90A5B14Q35118364-02457B96-F3BD-4C73-AAA9-7F2CD8044A75Q35206258-003683C0-F18D-4B86-B0F5-2BA02DF27D96Q35834909-29634365-A811-4661-9FB1-4AD15235688CQ36723728-CCB104F9-6625-449A-BEA4-AC5C4235141BQ37258632-62AFDE7E-624B-4DF3-9676-A6411CBA7AA9Q37591464-4E20C58C-5F7C-45D4-AD96-8A1D6AD0B022Q37678487-893ECF9F-0EAA-41BC-9BCC-19AAFBAC8D81Q38093624-DA70D21F-8868-401E-BD82-9DA4B5A4C671Q38110227-838EA92D-C36E-4516-89D1-19282784EC65Q38110619-EF3B1CAA-1A53-40BF-9493-5C7189D8F6A9Q38169198-B8524559-129E-4383-874C-54FB431CF4A9Q38181610-E654AACF-174A-45D8-852C-9E7F1767A620Q38229893-8DF5E567-ED0A-4601-8A76-C0C6FAB655A0Q38349779-CB8F9E1C-B564-4E8A-8890-0B23A6AD9756Q38542095-E45B60B5-6FB8-46AB-ABA3-D9A7C360862FQ38543700-22BEF70C-8741-401F-A65E-FEE42B6C2F8BQ38655324-5185709A-210F-42A2-9B19-A530497F3145Q38702290-F737257E-E85B-490B-8058-0FA2E407FDB9Q38761961-40436C08-8727-4C4A-982F-0EFAA7DD24E6Q38766379-AD295C4D-527A-4493-802E-1CDE701DE427Q38803278-0CBB9B84-930B-47C2-9EEA-99A850E51E41Q38853625-36DD64E7-0063-43F6-B06D-A184A32DEAF8Q38882099-7298F1AE-B3BE-4E69-852D-0E1AD2FBFC81Q38929939-65894DC6-BA95-4D83-A0EA-B29292E9FB7FQ38953721-37C1C78E-0FE7-4548-B0FD-D2A777A85167Q39039141-37D7063D-F04E-4A74-B0A2-843755261B88Q39096636-439B5385-722E-489F-BBF8-C857DAABD8A7Q40768273-433D83DA-6AAF-4E7A-84FA-44755CF50C8EQ41127816-704698E5-0C34-47BB-A321-8A1BFAB5C2EE
P2860
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@ast
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@en
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@nl
type
label
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@ast
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@en
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@nl
prefLabel
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@ast
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@en
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@nl
P2093
P2860
P1476
Jakinibs: a new class of kinase inhibitors in cancer and autoimmune disease
@en
P2093
Alexander Kotlyar
Apostolos Kontzias
Arian Laurence
John J O'Shea
Paul Changelian
P2860
P304
P356
10.1016/J.COPH.2012.06.008
P407
P577
2012-08-01T00:00:00Z